Promoting Medical Innovation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15260%2F17%3A73584087" target="_blank" >RIV/61989592:15260/17:73584087 - isvavai.cz</a>

Výsledek na webu

<a href="https://obd.upol.cz/id_publ/333163972" target="_blank" >https://obd.upol.cz/id_publ/333163972</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1377/hlthaff.2017.0803" target="_blank" >10.1377/hlthaff.2017.0803</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Promoting Medical Innovation

Popis výsledku v původním jazyce

In developed countries, governments and not-for-profit organizations invest heavily in biomedical research and drug development. Paradoxically, when scientists from Bayer Healthcare analyzed sixtyseven laboratory research projects, forty-seven of which were in the field of oncology, they found that only 25 percent of the projects had completely reproducible results. In another study, researchers from Amgen confirmed the results of only six of fifty-three landmark studies in the field of preclinical oncology or hematology. Recently, it was estimatedthat the cumulative prevalence of irreproducible results in preclinical research in general exceeds 50 percent and costs roughly $28 billion per year in the United States alone. I suggest that there is a need to raise awareness of these problems among physicians and to demand more resources for nonprofit funding of clinical trials of unpatentable drugs instead of irreproducible preclinical research.

Název v anglickém jazyce

Promoting Medical Innovation

Popis výsledku anglicky

In developed countries, governments and not-for-profit organizations invest heavily in biomedical research and drug development. Paradoxically, when scientists from Bayer Healthcare analyzed sixtyseven laboratory research projects, forty-seven of which were in the field of oncology, they found that only 25 percent of the projects had completely reproducible results. In another study, researchers from Amgen confirmed the results of only six of fifty-three landmark studies in the field of preclinical oncology or hematology. Recently, it was estimatedthat the cumulative prevalence of irreproducible results in preclinical research in general exceeds 50 percent and costs roughly $28 billion per year in the United States alone. I suggest that there is a need to raise awareness of these problems among physicians and to demand more resources for nonprofit funding of clinical trials of unpatentable drugs instead of irreproducible preclinical research.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30304 - Public and environmental health

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Health Affairs

ISSN

0278-2715

e-ISSN

—

Svazek periodika

36

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

1

Strana od-do

1518

Kód UT WoS článku

000407080200028

EID výsledku v databázi Scopus

2-s2.0-85027166929